The Use of Benzodiazepines and Risk of Incident Type 2 Diabetes in the General Population with Insomnia.

Tingting Zhao; Chang Liu; Shiyu Zhu; Shuang Wu; Xin Fang; Jian Shen; Meixiang Xiang; Yao Xie

doi:10.2174/0118715273430289251128102145

January 14, 2026

The Use of Benzodiazepines and Risk of Incident Type 2 Diabetes in the General Population with Insomnia.

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to determine whether benzodiazepine use increases the risk of developing type 2 diabetes in individuals with insomnia.
Conducted cohort analyses using data from UK Biobank participants.
Applied Mendelian randomisation to explore drug target effects.
Evaluated incident type 2 diabetes cases among benzodiazepine users versus non-users.
No significant increase in type 2 diabetes risk associated with benzodiazepine use was found.
Findings align across different analytical methods demonstrating consistency in results.

Implication

Cohort analysis assesses diabetes risk in insomnia individuals using benzodiazepines, suggesting no significant link.

Abstract

Evidence from both cohort analyses and drug target Mendelian randomisation suggests that BDZ use does not significantly increase the risk of T2DM among UK Biobank participants with insomnia.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhao et al. (2026) studied this question.

synapsesocial.com/papers/6975b306feba4585c2d6e8a9 https://doi.org/10.2174/0118715273430289251128102145

View at Publisher

Ask AI

Bookmark

Share

The Use of Benzodiazepines and Risk of Incident Type 2 Diabetes in the General Population with Insomnia.

Key Points

Implication

Abstract

Discussion

Cite This Study

The Use of Benzodiazepines and Risk of Incident Type 2 Diabetes in the General Population with Insomnia.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading